50 results found
Searchresult 1 - 10 of 50. You filter by “Hospital care”.
-
ACM studies: the insured’s diversity of wishes affects the negotiation balance between health insurers and hospitals
Health insurers must constantly find the right balance between the various wishes of insured. That affects their position in negotiations with hospitals.
-
ACM: room for collaboration involving the distribution of essential drugs for COVID-19 patients
Hospitals, hospital pharmacies, and pharmaceutical wholesalers are allowed to collaborate closely with each other during the current coronavirus (COVID-19) outbreak in order to prevent or reduce any shortages of essential drugs.
-
Room for collaborations as part of ‘the Right Care in the Right Place’
Many forms of collaborations are allowed. However, collaborations can also go too far. That is why ACM has provided more clarity in its ‘Policy Rule on the Right Care in the Right Place’.
-
ACM Policy Rule on arrangements as part of the movement called ‘The right care in the right place’ (JZOJP)
In this policy rule, ACM explains that it will not impose any fines if collaborations as part of the initiative called ‘the Right Care in the Right Place’ (in Dutch: De Juiste Zorg op de Juiste Plek) meet five criteria.
-
Health insurers and hospitals leave full potential of collective procurement of prescription drugs untapped
Hospitals and health insurers are not yet taking full advantage of the potential benefits that their collaborations in drug procurement are able to offer, according to the evaluation of the ‘Guidelines on collective procurement of prescription drugs’.
-
ACM: a broad-based effort is needed for long-term competition in anti-rheumatic prescription drugs
The expiration of patents and the market entry of competing drugs have led to drops in the net purchasing prices of TNF-alpha inhibitors. In order to guarantee their affordability in the future, a broad-based effort is needed.
-
Sector inquiry into TNF alpha inhibitors
ACM conducted a sector inquiry into TNF alpha inhibitors. The expiration of patents has led to lower prices. To guarantee their affordability in the future, competitors must be able to gain a solid position on the Dutch market.